Suzhou HVHa Medical Technology Development Co., Ltd. is committed to becoming a global leader in biosurgery technology. The company's mission is to build a biosurgery medical innovation technology platform, and its vision is to build a world-class, market-leading biosurgery technology company. Since its establishment in 2005, the company has focused on the research and development and application of cutting-edge fields such as biosurgery trauma repair,    orthopedic implants, and tissue engineering. We provide doctors with cutting-edge and efficient treatment solutions, surgical patients with better surgical treatment and better postoperative recovery, and improves the quality of life of patients, through a diversified product portfolio.

Relying on its five unique technology platforms - colloidal silver technology, hydrogel technology, bacterial cellulose technology, biological 3D technology and MT (metallothionein) technology, the company adheres to the trustworthy innovation concept, deeply explores the broad clinical needs, and forms a three-dimensional and full-coverage product structure with bacterial cellulose series products as the core, colloidal silver and hydrogel technology products, biological 3D technology products as auxiliary, Anong minimal invasive surgical instruments products as supplement, and metallothionein technology products as reserve.